Dr. Reddy’s reworking its biosimilars strategy

Dr Reddy's

Dr. Reddy’s was one of the first major pharma companies to start biosimilar development in 2005, but since then biosimilar movement within the company has slowed. The last major biosimilar launch for Dr. Reddy’s was in 2011, and companies such as Cipla, Biocon, and Intas have released multiple biosimilar drugs since. Dr. Reddy’s has been reworking its biosimilars strategy, and is planning to hold back in India in favor of making a larger global play in the coming years.

Read the source article at The Economic Times

About the Author

Related Posts

Leave a Reply